Pediatric Trial Evaluating COVID-19 Oral Antiviral Paxlovid Begins
The EPIC-PEDS study will include approximately 140 patients less than 18 years of age with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease.
The EPIC-PEDS study will include approximately 140 patients less than 18 years of age with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease.
Can proteomics identify biomarkers of infection, disease severity, and treatment
response in patients with non-tuberculous mycobacterial lung infection?
During the COVID-19 pandemic, there was a decrease in cardiac-related calls to EMS and a corresponding increase in out-of-hospital cardiac arrest.
Seventy percent of American adults could be vaccinated against COVID-19 by this summer, a new poll suggests.
A clinical trial is underway to assess the safety and effectiveness of mixing different types of COVID-19 booster shots in fully vaccinated adults.
COVID-19 symptom exacerbation is the leading cause of early acute-care hospital reencounters (ACHEs) after COVID-19 hospitalization.
Patients with immune-mediated inflammatory diseases (IMIDs) receiving background methotrexate have worse humoral and cellular immunogenicity to mRNA COVID-19 vaccines.
Forty-five percent of adults hospitalized for COVID-19 experienced functional decline impacting survival.
US officials on Monday warned all Americans not to visit Japan because of a spike in COVID-19 cases there just two months before the Tokyo Olympics are set to start.
The COVID-19 death toll in Latin America and the Caribbean has surpassed 1 million, Johns Hopkins University data show.